Teladoc Health, Inc. TDOC 深 沪
已收盘 03-27 16:00:00 美东时间
5.14
-0.380
-6.88%
华盛通- 最 高5.47
- 今 开5.44
- 成交量 453.54万股
- 最 低 5.12
- 昨 收 5.52
- 总市值 9.17亿
- 52周最高 9.77
- 市盈率 静 --
- 换手率 2.54%
- 52周最低 4.40
- 委 比 10.05%
- 总股本 1.78亿
- 历史最高 308.00
- 量 比 0.99
- 振 幅 6.34%
- 历史最低 4.40
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Barclays Maintains Equal-Weight on Teladoc Health, Lowers Price Target to $7
Barclays analyst Glen Santangelo maintains Teladoc Health (NYSE:TDOC) with a Equal-Weight and lowers the price target from $8.5 to $7.
03-26 20:47
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Deutsche Bank Upgrades Teladoc Health to Buy, Announces $11 Price Target
Deutsche Bank analyst George Hill upgrades Teladoc Health (NYSE:TDOC) from Hold to Buy and announces $11 price target.
03-10 23:47
Teladoc Health Stock Pops - Here's Why
Teladoc Health stock jumps after beating earnings estimates, even as cautious 2026 guidance and mixed analyst views emerge.
03-10 22:49
Teladoc jumps as Deutsche Bank upgrades on valuation
Teladoc Health added ~11% in the premarket on Tuesday after Deutsche Bank upgraded the telehealth provider to Buy from Hold, citing a compelling valuation and improving prospects for its mental health...
03-10 20:48
Lilly launches program to drive employee access to obesity care
Eli Lilly (LLY) announced on Thursday the launch of the Employer Connect platform, which enables employees to access its obesity therapy Zepbound at a lower cost through a network of pharmacies and a ...
03-05 20:38
Eli Lilly Targets Employer Coverage Gap With New Obesity Drug Access Platform
Eli Lilly (NYSE: LLY) launches Employer Connect platform on March 5, 2026, offering Zepbound tirzepatide KwikPen at $449 across all doses to expand employer-sponsored obesity coverage.
03-05 20:16
Lilly launches employer-connect platform to broaden weight-loss drug access
Lilly launches employer-connect platform to broaden weight-loss drug access March 5 (Reuters) - Eli Lilly LLY.N said on Thursday it had rolled out a platform to help employers connect with organizations offering low-cost benefits and comprehensive obesity-care programs, aiming to widen access to its
03-05 19:01
